HealthInvest Partners’s Pyxis Oncology PYXS Stock Holding History

HealthInvest Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.91M	Buy	966,459 +769,423	+390%	+$1.47M	0.78%	37
2026 Q1	$1.62M	Sell	197,036 -420,209	-68%	-$633K	0.52%	39
2025 Q4	$710K	Buy	+617,245	New	+$2.18M	0.23%	39

Other funds holding PYXS

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

HIMS

Hager Investment Management Services New London, New Hampshire $217M AUM 56.89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FUBT

First United Bank & Trust Oakland, Maryland $348M AUM 25.01% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

HealthInvest Partners's PYXS Position: Q2 2026 in Review

HealthInvest Partners increased its Pyxis Oncology (PYXS) stake by 390% in Q2 2026, buying an estimated $1.47M and bringing the position to 966,459 shares worth $2.91M. The position accounts for 0.78% of the portfolio, ranked #37.

HealthInvest Partners first reported a position in PYXS in Q4 2025 and has held it in 3 quarters since. 7 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

HealthInvest Partners held 966,459 shares of Pyxis Oncology worth $2.91M as of Q2 2026.
HealthInvest Partners bought 769,423 Pyxis Oncology shares in Q2 2026, an estimated $1.47M.
Pyxis Oncology made up 0.78% of HealthInvest Partners's portfolio in Q2 2026, its #37 holding.
HealthInvest Partners first reported a position in Pyxis Oncology in Q4 2025 and has held it in 3 quarters since.
7 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.